Inhibition of mitogen activated protein kinase activated protein kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo
Vein graft intimal hyperplasia remains the leading cause of graft failure, despite many
pharmacological approaches that have failed to translate to human therapy. We investigated
whether local suppression of inflammation and fibrosis with MMI-0100, a novel peptide
inhibitor of Mitogen Activated Protein Kinase Activated Protein Kinase II (MK2), would be an
alternative strategy to reduce cell proliferation and intimal hyperplasia. The cell permeant
peptide MMI-0100 was synthesized using standard Fmoc chemistry. Pharmacological doses …
pharmacological approaches that have failed to translate to human therapy. We investigated
whether local suppression of inflammation and fibrosis with MMI-0100, a novel peptide
inhibitor of Mitogen Activated Protein Kinase Activated Protein Kinase II (MK2), would be an
alternative strategy to reduce cell proliferation and intimal hyperplasia. The cell permeant
peptide MMI-0100 was synthesized using standard Fmoc chemistry. Pharmacological doses …